Boston Scientific added to ‘Top Picks’ list at Citi

Citi analyst Joanne Wuensch added Boston Scientific to the firm’s “Top Picks” list and reiterates a Buy rating on the shares with a $63 price target following the analyst day. Management reiterated 2023 guidance, set a long range plan revenue goal of 8%-10%, higher than expectations for 7%-9% and the current of 6%-8%, the analyst tells investors in a research note. The firm says the presentation was “chock-full of product details.”